Trifluoroacetic acid → N-(3-(1H-benzo[d]imidazol-2-yl)-1H-indazol-5-yl)-4,4-difluorocyclohexanecarboxamide
反応式
C(O)(C(F)(F)F)=O.[NH:8]1[C:12]2[CH:13]=[CH:14][CH:15]=[CH:16][C:11]=2[N:10]=[C:9]1[C:17]1[C:25]2[C:20](=[CH:21][CH:22]=[C:23]([NH:26][C:27]([CH:29]3[CH2:34][CH2:33][C:32]([F:36])([F:35])[CH2:31][CH2:30]3)=[O:28])[CH:24]=2)[N:19](C2CCCCO2)[N:18]=1>C(Cl)Cl>[NH:10]1[C:11]2[CH:16]=[CH:15][CH:14]=[CH:13][C:12]=2[N:8]=[C:9]1[C:17]1[C:25]2[C:20](=[CH:21][CH:22]=[C:23]([NH:26][C:27]([CH:29]3[CH2:30][CH2:31][C:32]([F:36])([F:35])[CH2:33][CH2:34]3)=[O:28])[CH:24]=2)[NH:19][N:18]=1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
TFA (0.5 mL, 6.490 mmol) was added to a solution of N-(3-(1H-benzo[d]imidazol-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)-4,4-difluorocyclo hexane carboxamide (10 mg) in CH2Cl2 (4 mL). The reaction mixture was stirred at room temperature for 24 h, and then the solvent was removed in vacuo. Purification by flash chromatography (6% CH3OH/CH2Cl2) afforded the title compound (6 mg) as an off-white solid. 1H NMR (400 MHz, CD3OD): δ 8.67 (s, 1H), 7.80 (m, 2H), 7.69 (d, 1H, J=9.2 Hz), 7.52 (m, 3H), 2.57 (m, 1H), 2.18 (m, 2H), 2.01 (m, 2H), 1.97-1.87 (m, 3H); ESI-MS [M+H]+: 396.3.